This HTML5 document contains 241 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01190/identifier/wikipedia/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01190/identifier/pharmgkb/
n12http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n30http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01190/identifier/pdb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01190/identifier/kegg-compound/
n13http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/mixture/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01190/identifier/pubchem-compound/
n7http://www.drugs.com/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01190/identifier/pubchem-substance/
n22http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB01190/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01190/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n32http://linked.opendata.cz/resource/drugbank/patent/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01190/identifier/national-drug-code-directory/
n33http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n29http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/property/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01190/identifier/chemspider/
n10http://www.rxlist.com/cgi/generic2/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01190/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01190
rdf:type
n3:Drug
n3:description
Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration.
n3:dosage
n13:271B5229-363D-11E5-9242-09173F13E4C5 n13:271B522A-363D-11E5-9242-09173F13E4C5 n13:271B522B-363D-11E5-9242-09173F13E4C5 n13:271B522C-363D-11E5-9242-09173F13E4C5 n13:271B5235-363D-11E5-9242-09173F13E4C5 n13:271B5236-363D-11E5-9242-09173F13E4C5 n13:271B5237-363D-11E5-9242-09173F13E4C5 n13:271B5231-363D-11E5-9242-09173F13E4C5 n13:271B5232-363D-11E5-9242-09173F13E4C5 n13:271B5233-363D-11E5-9242-09173F13E4C5 n13:271B5234-363D-11E5-9242-09173F13E4C5 n13:271B522D-363D-11E5-9242-09173F13E4C5 n13:271B522E-363D-11E5-9242-09173F13E4C5 n13:271B522F-363D-11E5-9242-09173F13E4C5 n13:271B5230-363D-11E5-9242-09173F13E4C5 n13:271B5238-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Daum RS: Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007 Jul 26;357(4):380-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17652653 # Klempner MS, Styrt B: Clindamycin uptake by human neutrophils. J Infect Dis. 1981 Nov;144(5):472-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6171600 # Lamont RF: Can antibiotics prevent preterm birth--the pro and con debate. BJOG. 2005 Mar;112 Suppl 1:67-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15715599 # Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC: Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother. 1989 May;33(5):618-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2751277
n3:group
approved
n3:halfLife
2.4 hours
n3:indication
For the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.
owl:sameAs
n22:DB01190 n33:DB01190
dcterms:title
Clindamycin
adms:identifier
n15:3745 n16:C06914 n17:27005 n18:DB01190 n20:Clindamycin n23:CLY n24:PA449035 n25:D00277 n26:0009-0331-02 n27:29029 n28:46506073
n3:mechanismOfAction
Systemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. Specifically, it binds primarily to the 23s RNA subunit. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles.
n3:packager
n4:271B51C2-363D-11E5-9242-09173F13E4C5 n4:271B51C3-363D-11E5-9242-09173F13E4C5 n4:271B51E8-363D-11E5-9242-09173F13E4C5 n4:271B51E9-363D-11E5-9242-09173F13E4C5 n4:271B51A8-363D-11E5-9242-09173F13E4C5 n4:271B51A9-363D-11E5-9242-09173F13E4C5 n4:271B51A6-363D-11E5-9242-09173F13E4C5 n4:271B51A7-363D-11E5-9242-09173F13E4C5 n4:271B51A4-363D-11E5-9242-09173F13E4C5 n4:271B51A5-363D-11E5-9242-09173F13E4C5 n4:271B51EC-363D-11E5-9242-09173F13E4C5 n4:271B51D3-363D-11E5-9242-09173F13E4C5 n4:271B51ED-363D-11E5-9242-09173F13E4C5 n4:271B51D4-363D-11E5-9242-09173F13E4C5 n4:271B51EA-363D-11E5-9242-09173F13E4C5 n4:271B51D1-363D-11E5-9242-09173F13E4C5 n4:271B51EB-363D-11E5-9242-09173F13E4C5 n4:271B51D2-363D-11E5-9242-09173F13E4C5 n4:271B51CF-363D-11E5-9242-09173F13E4C5 n4:271B51D0-363D-11E5-9242-09173F13E4C5 n4:271B51DB-363D-11E5-9242-09173F13E4C5 n4:271B51DC-363D-11E5-9242-09173F13E4C5 n4:271B51D9-363D-11E5-9242-09173F13E4C5 n4:271B51DA-363D-11E5-9242-09173F13E4C5 n4:271B51D7-363D-11E5-9242-09173F13E4C5 n4:271B51D8-363D-11E5-9242-09173F13E4C5 n4:271B51D5-363D-11E5-9242-09173F13E4C5 n4:271B51D6-363D-11E5-9242-09173F13E4C5 n4:271B51E3-363D-11E5-9242-09173F13E4C5 n4:271B51E4-363D-11E5-9242-09173F13E4C5 n4:271B51E1-363D-11E5-9242-09173F13E4C5 n4:271B51E2-363D-11E5-9242-09173F13E4C5 n4:271B51DF-363D-11E5-9242-09173F13E4C5 n4:271B51E0-363D-11E5-9242-09173F13E4C5 n4:271B51DD-363D-11E5-9242-09173F13E4C5 n4:271B51DE-363D-11E5-9242-09173F13E4C5 n4:271B519A-363D-11E5-9242-09173F13E4C5 n4:271B519B-363D-11E5-9242-09173F13E4C5 n4:271B5198-363D-11E5-9242-09173F13E4C5 n4:271B5199-363D-11E5-9242-09173F13E4C5 n4:271B5197-363D-11E5-9242-09173F13E4C5 n4:271B51A2-363D-11E5-9242-09173F13E4C5 n4:271B51A3-363D-11E5-9242-09173F13E4C5 n4:271B51A0-363D-11E5-9242-09173F13E4C5 n4:271B51A1-363D-11E5-9242-09173F13E4C5 n4:271B51CE-363D-11E5-9242-09173F13E4C5 n4:271B51E7-363D-11E5-9242-09173F13E4C5 n4:271B519E-363D-11E5-9242-09173F13E4C5 n4:271B519F-363D-11E5-9242-09173F13E4C5 n4:271B51CC-363D-11E5-9242-09173F13E4C5 n4:271B519C-363D-11E5-9242-09173F13E4C5 n4:271B51CD-363D-11E5-9242-09173F13E4C5 n4:271B519D-363D-11E5-9242-09173F13E4C5 n4:271B51CA-363D-11E5-9242-09173F13E4C5 n4:271B51CB-363D-11E5-9242-09173F13E4C5 n4:271B51B0-363D-11E5-9242-09173F13E4C5 n4:271B51B1-363D-11E5-9242-09173F13E4C5 n4:271B51AE-363D-11E5-9242-09173F13E4C5 n4:271B51AF-363D-11E5-9242-09173F13E4C5 n4:271B51AC-363D-11E5-9242-09173F13E4C5 n4:271B51AD-363D-11E5-9242-09173F13E4C5 n4:271B51AA-363D-11E5-9242-09173F13E4C5 n4:271B51AB-363D-11E5-9242-09173F13E4C5 n4:271B51B8-363D-11E5-9242-09173F13E4C5 n4:271B51B9-363D-11E5-9242-09173F13E4C5 n4:271B51B6-363D-11E5-9242-09173F13E4C5 n4:271B51B7-363D-11E5-9242-09173F13E4C5 n4:271B51B4-363D-11E5-9242-09173F13E4C5 n4:271B51B5-363D-11E5-9242-09173F13E4C5 n4:271B51B2-363D-11E5-9242-09173F13E4C5 n4:271B51B3-363D-11E5-9242-09173F13E4C5 n4:271B51C0-363D-11E5-9242-09173F13E4C5 n4:271B51C1-363D-11E5-9242-09173F13E4C5 n4:271B51BE-363D-11E5-9242-09173F13E4C5 n4:271B51E5-363D-11E5-9242-09173F13E4C5 n4:271B51BF-363D-11E5-9242-09173F13E4C5 n4:271B51E6-363D-11E5-9242-09173F13E4C5 n4:271B51BC-363D-11E5-9242-09173F13E4C5 n4:271B51BD-363D-11E5-9242-09173F13E4C5 n4:271B51BA-363D-11E5-9242-09173F13E4C5 n4:271B51BB-363D-11E5-9242-09173F13E4C5 n4:271B51C8-363D-11E5-9242-09173F13E4C5 n4:271B51C9-363D-11E5-9242-09173F13E4C5 n4:271B51C6-363D-11E5-9242-09173F13E4C5 n4:271B51C7-363D-11E5-9242-09173F13E4C5 n4:271B51C4-363D-11E5-9242-09173F13E4C5 n4:271B51C5-363D-11E5-9242-09173F13E4C5
n3:patent
n32:5266329 n32:7374747
n3:routeOfElimination
Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites.
n3:synonym
Cleocin (tn) Clindamycine Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside 7-CDL Clindamycinum 7(S)-Chloro-7-deoxylincomycin Clindamicina Clindamycin
n3:toxicity
Adverse effects include nausea (may be dose-limiting), diarrhea, pseudomembranous colitis, allergic reactions, hepatoxicity, transient neutropenia and eosinophilia and agranulocytosis. Pseudomembranous colitis occurs in 0.01 - 10% of patients and occurs more commonly than with other antibiotics. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.
n8:hasAHFSCode
n12:08-12-28-20 n12:84-04-04
n3:foodInteraction
Take with food.
n3:mixture
n19:271B5196-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
92-94%
n3:salt
n3:synthesisReference
Donald E. Ayer, Carl A. Schlagel, Gordon L. Flynn, "Topical clindamycin preparations." U.S. Patent US4018918, issued January, 1971.
n29:hasConcept
n30:M0004561
foaf:page
n7:clindamycin.html n10:clindam.htm
n3:IUPAC-Name
n11:271B523D-363D-11E5-9242-09173F13E4C5
n3:InChI
n11:271B5243-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n11:271B5242-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n11:271B523F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n11:271B5240-363D-11E5-9242-09173F13E4C5
n3:SMILES
n11:271B5241-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n11:271B523B-363D-11E5-9242-09173F13E4C5 n11:271B5253-363D-11E5-9242-09173F13E4C5
n3:logP
n11:271B523C-363D-11E5-9242-09173F13E4C5 n11:271B5239-363D-11E5-9242-09173F13E4C5 n11:271B5255-363D-11E5-9242-09173F13E4C5
n3:logS
n11:271B523A-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:D10AF01 n9:G01AA10 n9:J01FF01
n3:H-Bond-Acceptor-Count
n11:271B5249-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n11:271B524A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n11:271B5244-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n11:271B5245-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n11:271B5247-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n11:271B5246-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n11:271B5248-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed after oral administration with peak serum concentrations observed after about 45 minutes. Absorption of an oral dose is virtually complete (90%) and the concomitant intake of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Clindamycin does not penetrate the blood brain barrier.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
18323-44-9
n3:category
n3:containedIn
n5:271B521A-363D-11E5-9242-09173F13E4C5 n5:271B5217-363D-11E5-9242-09173F13E4C5 n5:271B5218-363D-11E5-9242-09173F13E4C5 n5:271B5215-363D-11E5-9242-09173F13E4C5 n5:271B5216-363D-11E5-9242-09173F13E4C5 n5:271B5223-363D-11E5-9242-09173F13E4C5 n5:271B5224-363D-11E5-9242-09173F13E4C5 n5:271B5221-363D-11E5-9242-09173F13E4C5 n5:271B5222-363D-11E5-9242-09173F13E4C5 n5:271B521F-363D-11E5-9242-09173F13E4C5 n5:271B5220-363D-11E5-9242-09173F13E4C5 n5:271B521D-363D-11E5-9242-09173F13E4C5 n5:271B521E-363D-11E5-9242-09173F13E4C5 n5:271B51F3-363D-11E5-9242-09173F13E4C5 n5:271B51F4-363D-11E5-9242-09173F13E4C5 n5:271B51F1-363D-11E5-9242-09173F13E4C5 n5:271B51F2-363D-11E5-9242-09173F13E4C5 n5:271B51EF-363D-11E5-9242-09173F13E4C5 n5:271B51F0-363D-11E5-9242-09173F13E4C5 n5:271B51EE-363D-11E5-9242-09173F13E4C5 n5:271B51FB-363D-11E5-9242-09173F13E4C5 n5:271B51FC-363D-11E5-9242-09173F13E4C5 n5:271B51F9-363D-11E5-9242-09173F13E4C5 n5:271B51FA-363D-11E5-9242-09173F13E4C5 n5:271B51F7-363D-11E5-9242-09173F13E4C5 n5:271B51F8-363D-11E5-9242-09173F13E4C5 n5:271B51F5-363D-11E5-9242-09173F13E4C5 n5:271B51F6-363D-11E5-9242-09173F13E4C5 n5:271B5203-363D-11E5-9242-09173F13E4C5 n5:271B5204-363D-11E5-9242-09173F13E4C5 n5:271B5201-363D-11E5-9242-09173F13E4C5 n5:271B5202-363D-11E5-9242-09173F13E4C5 n5:271B51FF-363D-11E5-9242-09173F13E4C5 n5:271B5200-363D-11E5-9242-09173F13E4C5 n5:271B51FD-363D-11E5-9242-09173F13E4C5 n5:271B51FE-363D-11E5-9242-09173F13E4C5 n5:271B5227-363D-11E5-9242-09173F13E4C5 n5:271B5228-363D-11E5-9242-09173F13E4C5 n5:271B5225-363D-11E5-9242-09173F13E4C5 n5:271B5226-363D-11E5-9242-09173F13E4C5 n5:271B520B-363D-11E5-9242-09173F13E4C5 n5:271B520C-363D-11E5-9242-09173F13E4C5 n5:271B5209-363D-11E5-9242-09173F13E4C5 n5:271B520A-363D-11E5-9242-09173F13E4C5 n5:271B5207-363D-11E5-9242-09173F13E4C5 n5:271B5208-363D-11E5-9242-09173F13E4C5 n5:271B5205-363D-11E5-9242-09173F13E4C5 n5:271B5206-363D-11E5-9242-09173F13E4C5 n5:271B5213-363D-11E5-9242-09173F13E4C5 n5:271B5214-363D-11E5-9242-09173F13E4C5 n5:271B5211-363D-11E5-9242-09173F13E4C5 n5:271B5212-363D-11E5-9242-09173F13E4C5 n5:271B520F-363D-11E5-9242-09173F13E4C5 n5:271B5210-363D-11E5-9242-09173F13E4C5 n5:271B520D-363D-11E5-9242-09173F13E4C5 n5:271B520E-363D-11E5-9242-09173F13E4C5 n5:271B521B-363D-11E5-9242-09173F13E4C5 n5:271B521C-363D-11E5-9242-09173F13E4C5 n5:271B5219-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n11:271B524F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n11:271B5251-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n11:271B5252-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n11:271B5254-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n11:271B524E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n11:271B524D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n11:271B5250-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n11:271B523E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n11:271B524B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n11:271B524C-363D-11E5-9242-09173F13E4C5